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Introduction
Obstructive sleep apnoea (OSA) affects ß9-38% of the general adult population, ß13-33% of men and ß6-19% of women, prevalence rates that increase with age (Senaratna et al. 2016) . Obstructive sleep apnoea is characterized by repetitive apnoeas during sleep attributable to closure of the upper airway and resulting in chronic intermittent hypoxia (IH) and hypercapnia, oscillations in intrathoracic pressure, surges in sympathetic nerve activity, blood pressure and cerebral blood flow (CBF), and sleep fragmentation (Dempsey et al. 2010) .
To classify OSA severity, several metrics are used. These include the apnoea-hypopnoea index (AHI; the number of apnoeas and hypopnoeas per hour of sleep), the respiratory disturbance index [RDI; the number of apnoeas, hypopnoeas and respiratory effort-related arousals (RERAs) per hour of sleep] and the oxygen desaturation index [ODI; the number of times arterial oxygen saturation (S aO 2 ) decreases by ࣙ3-4% from baseline per hour of sleep]. For all metrics, a value less than five is considered normal, 5-15 is considered mild OSA, 15-30 is considered moderate OSA, and >30 is considered severe OSA (Berry et al. 2015) .
Based upon longitudinal, cross-sectional and observational studies, international guidelines have identified OSA as an independent risk factor for cardiovascular and cerebrovascular disease (Chobanian et al. 2003; Baguet et al. 2006; Somers et al. 2008; Lévy et al. 2011) . Although all the physiological changes outlined above that occur during repetitive apnoeas likely contribute, chronic IH is believed to be the primary mediator of increased risk of vascular disease in OSA (Somers et al. 2008) . Figure 1 highlights putative mechanisms through which IH has been found to impact the cerebral and peripheral vasculatures detrimentally, thus predisposing patients with OSA to the consequences of vascular disease. While data from both animal and human experimental models of IH support this notion (Table 1 and Fig. 1 ), it is important to note two limitations of these models. First, the degree of IH used within many animal studies typically mimics severe-to-very severe OSA and thus reflects only a small proportion of OSA patients seen clinically. Second, within both animal and human experimental models, IH is initiated abruptly, which is not what occurs clinically, where OSA severity, and thus IH exposure, develops gradually over time. The severity of IH is an important consideration because the relationship between OSA and declining vascular health is dose dependent, with recent evidence indicating that mild OSA, in conjunction with common co-morbidities, may decrease mortality risk when compared with non-OSA patients with similar co-morbidities (Marshall et al. 2014) . Furthermore, a mild degree of IH appears protective from ischaemic events such as myocardial infarction and stroke by minimizing infarct size (Béguin et al. 2005; Jackman et al. 2014 ) and promoting neurogenesis (Gozal et al. 2003; Tsai et al. 2011 Tsai et al. , 2013 Intermittent hypoxia-induced increases in sympathetic activity, oxidative stress, inflammation, endothelial dysfunction and carotid body activity and decreased nitric oxide (NO) bioavailability are reported to have detrimental effects on the brain/cerebrovasculature and the heart/cardiovascular systems that contribute to the increased risk of stroke, white matter hyperintensities, cognitive decline, hypertension, tachycardia, myocardial infarction, arrhythmia and heart failure associated with untreated obstructive sleep apnoea (OSA). Additionally, IH alters kidney function via several mechanisms (dashed box) and augments activation of the renin-angiotensin system, which contributes to the increased risk of cardiovascular disease associated with untreated OSA. Cross-sectional, observational and longitudinal clinical (OSA patient) studies have been fundamental in showing the independent association between OSA and cardiovascular disease (right column) and furthering the hypothesis that OSA-induced IH was the main feature of OSA contributing to this increased risk of vascular disease. Subsequently, animal experimental IH models have been essential in enhancing our knowledge of the molecular mechanisms through which IH disrupts the proper functioning of the physiological systems impacted by OSA (left column). Finally, recently developed human experimental models that better mimic OSA-related IH are now helping to determine whether the findings from animal studies of IH-induced mechanisms responsible for disrupted vascular regulation are translatable to the intact human (middle column).
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Obstructive sleep apnoea and vascular disease
The first strong evidence supporting OSA as an independent risk factor for vascular disease was reported by Peppard et al. (2000) from the Wisconsin Sleep Cohort Study, who found that individuals with an AHI of 1-4.9, 5-14.9 or ࣙ15 at baseline were respectively 1.4, 2.0 and 2.9 times more likely to develop hypertension within the next 4 years compared with individuals without OSA (AHI = 0). This increased risk of hypertension was independent of age, sex, body mass index (BMI), neck and waist circumferences, baseline blood pressure and alcohol consumption. This independent relationship between OSA and hypertension has since been corroborated by a more recent longitudinal study (Marin et al. 2012) , as well as several cross-sectional (Grote et al. 2000; Lavie et al. 2000; Nieto et al. 2000; Punjabi et al. 2008 ) and observational studies (Marin et al. 2005; Gottlieb et al. 2014) . However, the association between OSA and hypertension is not without debate. O'Connor et al. (2009) Furthermore, in a meta-analysis, Fava et al. (2014) showed that treatment with continuous positive airway pressure (CPAP) produces only modest reductions of systolic and diastolic blood pressures (2.2 ± 0.7 and 1.9 ± 0.7 mmHg, respectively). Also, a higher baseline AHI was associated with a greater decrease in systolic blood pressure (Fava et al. 2014) . Hence, the relationship between OSA and hypertension remains modest at best, except for patients with severe OSA. With respect to cerebrovascular disease, the best evidence supporting OSA as an independent risk factor also came from the Wisconsin Sleep Cohort Study. In cross-sectional analyses, Arzt et al. (2005) found that subjects with an AHI of 5-19.9 had lower odds (OR = 0.49) whereas subjects with an AHI ࣙ 20 had higher odds (OR = 3.8) to have suffered a stroke than individuals without OSA (AHI ࣘ 5) after controlling for age, sex, BMI, alcohol consumption, cigarette smoking, hypertension and diabetes. In a longitudinal component consisting of a 4 year follow-up, after controlling for age, sex and BMI, subjects with an AHI between 5 and 19.9 at baseline had lower odds (OR = 0.29) whereas subjects with an AHI ࣙ 20 had higher odds (OR = 3.1) of suffering a first ever stroke compared with subjects with an AHI ࣘ 5, although these differences were not statistically significant. Likewise, Yaggi et al. (2005) reported OSA patients to be at higher risk of stroke compared with OSA-free control subjects [hazard ratio (HR) = 1.97] after controlling for age, sex, race, smoking status, alcohol consumption, BMI, diabetes, hyperlipidaemia, atrial fibrillation and hypertension. In addition, a stepwise increase in stroke risk and all-cause mortality was observed for increasing OSA severity, with the HR being 1.75 for mild OSA (AHI = 4-12), 1.74 for moderate OSA (AHI = 13-36) and 3.30 for severe OSA (AHI ࣙ 36) compared with individuals with an AHI ࣘ 3. Subsequent longitudinal studies support the independent association between OSA and cerebrovascular disease (Munoz et al. 2006; Redline et al. 2010) , but similar to findings between OSA and the risk of hypertension, this relationship is strongest for patients with severe OSA, whereas a detrimental relationship between mild OSA and cerebrovascular disease remains unclear. Furthermore, though OSA is recognized to increase the risk of stroke occurrence, evidence is equivocal with regard to the impact of OSA treatment with CPAP on functional outcomes for patients who suffer a stroke. In one randomized controlled trial, compared with stroke patients with OSA who received standard rehabilitation, patients also treated with CPAP for 4 weeks post-stroke showed greater improvement in overall stroke-related impairment, but not in mobility (6 min walk test) or neurocognitive function (Ryan et al. 2011) . Similarly, a recent double-blind randomized controlled trial comparing CPAP to sham-CPAP treatment of OSA in stroke patients found no significant benefit of CPAP on a functional independence measure aimed at assessing global disability (Khot et al. 2016 ). However, a beneficial effect of CPAP was observed on the cognitive component of this functional outcome measure. Unfortunately, these two randomized controlled trials (Ryan et al. 2011; Khot et al. 2016 ) had relatively small sample sizes and thus were likely to be statistically underpowered to observe an improvement in function.
Finally, OSA is also reported to be an independent risk factor for coronary artery disease (Peker et al. 1999; Gottlieb et al. 2010; Kent et al. 2013; Campos-Rodriguez et al. 2014; Kwon et al. 2014) , myocardial infarction (Hung et al. 1990; Marin et al. 2005) , cardiac arrhythmia (Mehra et al. 2006) , silent cerebral infarction (Cho et al. 2013) and white matter hyperintensities of presumed vascular origin (Patel et al. 2015) . Again, the greatest risks being associated with moderate-to-severe OSA. Notwithstanding these associations, recent findings from the Multicentre Obstructive Sleep Apnoea Interventional Cardiovascular (MOSAIC) and Sleep Apnea Cardiovascular Endpoints (SAVE) studies report that treatment of OSA with CPAP did not improve either the calculated vascular risk or have long-term cardiovascular benefits, respectively. Specifically, in the MOSAIC study Craig et al. (2012) randomized OSA patients to treatment with CPAP or standard care and found that 6-8 months of CPAP did not improve the calculated 5 year risk of a fatal cardiovascular event; a finding that was similar between patients who used CPAP for ࣙ4 h per night (the recommended minimum required to improve vascular health; Gay et al. 2006) and patients who used CPAP for <4 h per night. Likewise, within the SAVE study McEvoy et al. (2016) randomized patients with established cardiovascular disease and moderate-to-severe OSA to treatment with CPAP or usual care and found no difference in composite cardiovascular outcomes over a mean of 3.7 years. However, the mean duration of CPAP use within the SAVE study was only 3.3 h per night, and no comparison was made between patients who used CPAP for ࣙ4 h per night and patients who used CPAP for <4 h per night. Thus it is still not known whether adherent CPAP treatment (i.e. usage for ࣙ4 h per night) would have provided a greater improvement in the composite cardiovascular outcomes.
Obstructive sleep apnoea, mortality and age.
Obstructive sleep apnoea is also associated with increased mortality (He et al. 1988; Gami et al. 2005; Yaggi et al. 2005; Lavie, 2007; Marin et al. 2012) , with younger patients being at the greatest risk (He et al. 1988; Grote et al. 2000; Lavie, 2007) . Though He et al. (1988) first reported OSA patients <50 years of age were at greater risk for mortality than those ࣙ50 years of age, it was not until Lavie et al. (2005) conducted a mortality study of 13,853 adult men aged 20-93 years that this relationship received greater attention. Comparing relative mortality rates of male OSA patients to the overall mortality rate of the male Israeli population, mortality risk increased progressively with RDI >10 (reference group RDI ࣘ 10). However, mortality risk for OSA patients with an RDI >50 decreased with advancing age. Men aged 20-49 years with an RDI ࣙ 50 had higher mortality rates than the general population, whereas the mortality rate was similar between OSA patients with an RDI >50 and ࣙ50 years of age and their general population counterparts. Interestingly, the age-adjusted mortality rate of men aged 50-69 years with a RDI ࣘ 30 was lower than that of the general population, whereas there was no difference in the age-adjusted mortality rate for men aged 30-49 or >70 years with a RDI ࣘ 30 compared with the general population.
Using 20 year follow-up data, Marshall et al. (2014) also investigated the association between OSA and all-cause mortality, cardiovascular disease, coronary artery disease, stroke and cancer. Dividing their cohort into mild (5 ࣙ RDI <15) and moderate-to-severe OSA (RDI ࣙ 15) they found that moderate-to-severe OSA was associated with greater risk of overall mortality (HR = 4.2) compared with non-OSA subjects after adjustment for confounding factors. In contrast, patients with mild OSA (RDI = 5-14) had lower mortality risk compared with non-OSA subjects A. E. Beaudin and others (HR = 0.51) in the fully adjusted model controlling for age, sex, BMI, smoking status, cholesterol, mean arterial pressure, diabetes and angina. No difference in mortality risk between mild OSA patients and non-OSA patients was observed in the unadjusted model. Thus, mild OSA was suggested to be protective against the effects of clustered cardiometabolic risk factors (i.e. patients with mild OSA and multiple co-morbidities may be at a lower risk of death than non-OSA individuals with similar co-morbidities).
Overall, data suggest that developing OSA later in life might be protective against mortality (Lavie & Lavie, 2006) , but the mechanisms for this improved mortality risk are incompletely understood. Although, as we discuss in the 'Intermittent hypoxia and age' section below, older age is associated with a lower susceptibility to the detrimental effects of OSA-induced IH (Quintero et al. 2016) , differences in OSA aetiology between older and younger OSA patients are also likely to contribute to the observed protective effect of advancing age on OSA-related mortality. Typically, with ageing, the arousal threshold is reduced and individuals experience greater sleep fragmentation, which work synergistically to reduce total sleep time (Zepelin et al. 1984; Vienne et al. 2016) . As a result, older patients with OSA may awaken and resume breathing earlier in response to an apnoea or hypopnoea and may not experience as many respiratory events during a night of sleep compared to younger patients. Consequently, older OSA patients may experience less nocturnal hypoxaemia for a given AHI or have less severe OSA compared with their younger counterparts. These are important differences because, as will be discussed below, the duration and degree of IH have important implications for the progression of OSA-related vascular disease. Alternatively, the protective effect of older age against OSA-related mortality may be consequential to younger individuals with untreated OSA not surviving into older age. As such, only patients resistant to the vascular consequences of OSA survive into later life.
Obstructive sleep apnoea and vascular regulation
Mechanisms implicated in the increased risk of vascular disease in OSA are multifactorial, but are believed to include sympathetic activation, endothelial dysfunction and altered peripheral and cerebral vascular regulation (Somers et al. 2008) . Furthermore, as OSA is associated with intermittent hypoxia and hypercapnia, how the peripheral and cerebral vasculatures respond to these two chemical stimuli is of great interest, as impaired responses could lead to diminished perfusion and tissue ischaemia during apnoea (Dempsey et al. 2010) . In the following sections, this review will focus on studies investigating sympathetic activity, endothelial function and peripheral and cerebral vascular responses to hypoxia and hypercapnia in OSA patients.
Sympathetic function.
There is considerable evidence indicating that augmented sympathetic nervous activity (SNA) is a primary contributor to the increased risk and prevalence of hypertension and vascular disease in untreated OSA Lavie & Lavie, 2012) . Initial data showing that SNA was elevated in OSA came from studies reporting elevated urinary and plasma catecholamines in OSA patients compared with OSA-free control subjects (Fletcher et al. 1987; Marrone et al. 1993; Dimsdale et al. 1995) . These findings have since been supported by direct recordings of greater muscle SNA (MSNA) in OSA patients during wakefulness and sleep compared to individuals without OSA (Leuenberger et al. 1995; Somers et al. 1995; Narkiewicz et al. 1998) . Additionally, OSA-induced elevations in MSNA have recently been reported to be related to both structural and functional changes within brain regions that are directly, and indirectly, involved in regulating brainstem sympathetic outflow (Fatouleh et al. 2014; Henderson et al. 2016) . Furthermore, treatment of OSA with CPAP decreases urinary and plasma catecholamines and MSNA (Fletcher et al. 1987; Marrone et al. 1993; Somers et al. 1995; Narkiewicz et al. 1999a; Lundblad et al. 2015) , improvements associated with changes in brainstem structure and function (Henderson et al. 2016 ).
Endothelial function. The vascular endothelium is a monolayer of cells lining the lumen of blood vessels that regulates peripheral and cerebral vascular tone in response to physical and chemical stimuli. Thus, endothelial dysfunction has important implications for vasomotor function and plays a crucial role in cardiovascular and cerebrovascular disease (Flammer et al. 2012) . Using venous occlusion plethysmography, Carlson et al. (1996) first reported that acetylcholine-induced vasodilatation (an endothelium-dependent response) was blunted in OSA patients compared to age-and BMI-matched control subjects independent of hypertension. Subsequently, Kato et al. (2000) also reported that newly diagnosed obese OSA patients also had lower acetylcholine-induced forearm vasodilatation compared to obese age-matched control subjects. These early findings have since been corroborated by additional patient studies (Kraiczi et al. 2001; Ip et al. 2004; Nieto et al. 2004; Duchna et al. 2005; Lattimore et al. 2006; Cross et al. 2008) . Furthermore, greater endothelial dysfunction has been positively associated with increasing AHI (Ip et al. 2004) , ODI (Cross et al. 2008 ) and nocturnal time with S aO 2 < 90% (Kraiczi et al. 2001; Nieto et al. 2004) , and treatment of OSA with CPAP improves endothelial function (Ip et al. 2004; Duchna et al. 2005; Lattimore et al. 2006; Cross et al. 2008 ), a beneficial effect attributed to the removal of IH. In the context of this review, it is important to note that, to our knowledge, there is no evidence to indicate that mild OSA has any beneficial effects on endothelial function. Obstructive sleep apnoea, intermittent hypoxia and vascular regulation Peripheral vasculature. Untreated OSA patients are typically assumed to have an exaggerated pressor response to hypoxia, although this is not a consistent finding. Hedner et al. (1992) assessed the pressor response to hypoxia and found that OSA patients had a larger response to eucapnic hypoxia compared to control subjects and that a higher AHI was associated with a greater response. Importantly, as hypertensive and normotensive patients had similar responses, the greater pressor response was not attributable to prevailing hypertension. Narkiewicz et al. (1999b) supported this earlier finding when they reported that newly diagnosed, normotensive OSA patients had greater pressor responses to hypoxia compared with ageand BMI-matched control subjects. However, studies performed around the same time, as well as more recently, have found no difference in the pressor response to hypoxia between OSA and control subjects Leuenberger et al. 1996; Remsburg et al. 1999; Imadojemu et al. 2007; Foster et al. 2008; Reichmuth et al. 2009 ). The reason for these discordant results likely reflects the various hypoxic challenges used within the studies. Therefore, although OSA patients are assumed to have a sensitized pressor response to hypoxia (Smith & Pacchia, 2007) , currently the majority of data now indicate that this is not the case.
Contrary to hypoxia, there are fewer studies assessing the pressor response to hypercapnia, but the results are more consistent; OSA is not associated with an elevated pressor response to hypercapnia (Reichmuth et al. 2009; Foster et al. 2009b; Ryan et al. 2014) .
For peripheral blood flow responses to hypoxia, findings are equivocal (Remsburg et al. 1999; Reichmuth et al. 2009; Moradkhan et al. 2010) . Using venous occlusion plethysmography and the same progressive isocapnic hypoxia challenge (S aO 2 = 90, 85 and 80%; 5 min stages), both Remsburg et al. (1999) and Reichmuth et al. (2009) reported that OSA patients have lower forearm vasodilatation compared to age-matched control subjects but this improves with 6-12 weeks of CPAP treatment (Reichmuth et al. 2009 ). Interestingly, a study using poikilocapnic hypoxia [inspired fraction of O 2 (F I,O 2 ) = 10%] and ultrasound assessment of brachial and femoral blood flow found no difference in blood flow responses between OSA patients and control subjects. However, these contrasting findings are again likely to be the result of differences in experimental design (blood flow measurement and hypoxic test). With respect to hypercapnia, one study has investigated the peripheral blood flow response to hypercapnia and reported no difference between OSA patients and control subjects (Reichmuth et al. 2009 ).
Lastly, OSA is reported to promote adaptations in the peripheral microvasculature, as severe OSA patients (AHI = 42.4) have been found to have greater tibialis anterior muscle microvascularization (i.e. percentage of capillaries expressing vascular endothelial growth factor and proliferating capillaries) compared to control subjects (Wåhlin Larsson et al. 2008; Wåhlin-Larsson et al. 2009 ). As this adaptation occurred while the predicted aerobic capacity remained lower in OSA patients compared to control subjects (Wåhlin Larsson et al. 2008) , it suggests that angiogenesis occurs to compensate for tissue hypoxaemia during sleep, which may be advantageous for muscle survival but without functional benefit.
Cerebrovasculature. Two studies have assessed the CBF response to hypoxia in OSA patients, with concordant findings. First, Foster et al. (2007a) reported that relatively young (41 ± 2 years; mean ± SEM), newly diagnosed, very severe OSA patients (AHI = 101 ± 10) had lower CBF responses to hypoxia compared to age-and BMI-matched control subjects. In addition, the CBF response to hypoxia was negatively correlated with AHI and positively correlated with mean nocturnal S aO 2 . These findings were corroborated by Reichmuth et al. (2009) , who also found that relatively young (36.1 ± 1.7 years) newly diagnosed patients with moderate-to-severe OSA (AHI = 68.9 ± 6.7) had lower hypoxic cerebrovascular reactivity compared to age-matched control subjects. Similar to Foster et al. (2007a) , a higher AHI and greater time with S aO 2 <90% during sleep were associated with lower cerebrovascular responses to hypoxia (Reichmuth et al. 2009 ). Finally, both Foster et al. (2007a) and Reichmuth et al. (2009) found that treatment of OSA with CPAP for 4-6 weeks improved the cerebrovascular response to hypoxia, thus implicating OSA, and OSA-related IH, as the principal contributors to the initial impairment.
In contrast to hypoxia, numerous studies have assessed the CBF response to hypercapnia in untreated OSA patients, using many different experimental approaches with equivocal results. All studies using steady-state hypercapnic challenges report that OSA patients have similar responses to non-OSA control subjects (Urbano et al. 2008; Foster et al. 2009b) . Using a progressive hyperoxic hypercapnic challenge, one study reported that OSA patients had lower CBF responses compared with age-matched control subjects (Reichmuth et al. 2009 ), while the same group also found that the CBF response to hypercapnia was negatively correlated with AHI and positively correlated with the mean S aO 2 during sleep . Subsequently, Ryan et al. (2014) found no difference in the CBF response to progressive hyperoxic hypercapnia between OSA patients and age-and BMI-matched control subjects. Finally, studies assessing CBF responses to a standardized breath hold have all reported OSA patients to have a lower CBF response compared to control subjects (Siebler & Nachtmann, 1993; Diomedi et al. 1998; Placidi et al. 1998; Prilipko et al. 2014; Coloma Navarro et al. 2016) . Although the principal stimulus to CBF during breath holds is A. E. Beaudin and others hypercapnia (Przybylowski et al. 2003) , breath holds have a degree of hypoxia, particularly if prolonged. Thus, it is of note that Ryan et al. (2014) found no difference between OSA patients and control subjects in response to a hypoxic-hypercapnic challenge. Therefore, current data indicate that OSA patients have an impaired cerebrovascular response to hypoxia that is associated with OSA severity, but there is still debate regarding the impact of OSA on the hypercapnic CBF response.
In contrast to the studies cited above that have assessed cerebrovascular responses to hypoxia and hypercapnia in OSA patients during wakefulness, OSA patients primarily experience intermittent hypoxia and hypercapnia during sleep. This is an important limitation to highlight because CBF responses to hypoxia and hypercapnia are lower during non-rapid eye movement sleep compared to wakefulness (Meadows et al. 2003 (Meadows et al. , 2004 (Meadows et al. , 2005 . Consequently, untreated OSA patients may be at greater risk of suffering an ischaemic event during sleep when the CBF responses to hypoxia and hypercapnia are further impaired, although this still needs to be investigated.
Another component of cerebrovascular regulation reported to be disrupted by OSA is autoregulation (Urbano et al. 2008; Nasr et al. 2009 ). Autoregulation is the mechanism used by the cerebral vasculature to maintain a relatively constant blood flow during fluctuations in perfusion pressure (i.e. blood pressure). When cerebral autoregulation is impaired, cerebral blood flow passively follows changes in systemic blood pressure, increasing the risk of cerebral ischaemia during hypotension and cerebrovascular damage during surges in blood pressure, such as those that occur at the termination of an apnoea (Waltz et al. 2016) . We recently assessed cerebral autoregulation using multiple coherence and transfer function analyses in a population of normotensive OSA patients free from overt cardiovascular risk factors (Waltz et al. 2016) . We found that the capacity to buffer surges in blood pressure was lower during normoxia for patients with an RDI >33.1, whereas in patients with an RDI ࣘ 33.1 this buffering capacity was not different from that of control subjects. This finding suggests a dose-response relationship between disease severity and alterations in cerebral autoregulation. However, during isocapnic-hypoxia this alteration in cerebral autoregulation was no longer present in the patients with an RDI >33.1, suggesting adaptation to hypercapnic-hypoxia during apnoeic events in patients with severe disease. Furthermore, in the same cohort, we found that the cerebral blood flow response to hypoxia was not altered in moderate-to-severe OSA patients compared with control subjects (Beaudin AE, Hanly PJ, Raneri JK, Sajobi TT, Anderson TJ & Poulin MJ, unpublished data). Given that cerebral autoregulation is maintained by larger vessels (>200 µm; Koller & Toth, 2012) , whereas the increase in CBF resulting from hypoxia is primarily regulated by the capillaries (Hall et al. 2014) , this suggests that moderate-to-severe OSA has differential effects on the vasculature depending upon which cerebrovascular response is being investigated (e.g. CBF response to hypoxia or cerebral autoregulation).
Intermittent hypoxia and vascular regulation
As indicated above and highlighted in Fig. 1 , IH is believed to be the primary feature of untreated OSA responsible for the increased risk of vascular disease in OSA, but IH also has beneficial physiological effects. It has been harnessed to improve oxygen consumption in the elderly (Burtscher et al. 2004) and to improve vascular function and reduce blood pressure in hypertensive individuals (Serebrovskaya et al. 2008; Lyamina et al. 2011) . However, the IH profile used in these studies is very different from that observed in OSA, and we refer the reader to recent reviews for greater detail (Mateika et al. 2015; Verges et al. 2015) . The following sections will review findings from animal and human experimental IH models that mimic OSA-related IH more closely and its impact on SNA, endothelial function and vascular regulation, highlighting both the detrimental and potentially beneficial effects of IH. Additional details for the studies cited are provided in Table 1 .
Detrimental effects of intermittent hypoxia.
Sympathetic nervous activity. The first study to investigate IH as a potential mechanism leading to hypertension in OSA was published by Fletcher et al. (1992c) . In their seminal study, rats exposed to hypoxia every 30 s (F I,O 2 nadir = 3-5%) for 7 h day −1 for 35 days during their normal sleep time increased mean blood pressure by 13.7 mmHg. Follow-up studies confirmed that sympathetic activation was integral to the IH-induced increase in blood pressure; carotid body denervation (Fletcher et al. 1992a) , chemical sympathetic denervation (Fletcher et al. 1992b ) and adrenal demedullation (Lesske et al. 1997 ) all prevented IH-induced increases in blood pressure. Supporting these findings are direct recordings of elevated cervical (Greenberg et al. 1999) , lumbar (Marcus et al. 2010 ) and renal (Huang et al. 2009 ) SNA following IH exposures mimicking moderate-to-severe OSA.
Similar to animal studies, exposure of healthy humans to 4 days of IH [2 min hypoxia (S aO 2 nadir = 80-85%) followed by 2 min of euoxia for 6 h day −1 ], 14 days of IH (2 min of F I,O 2 at 13% followed by 15 s of 100% oxygen for 8-9 h night −1 ) and 6 h of IH [1 min hypoxia (S aO 2 nadir = 80-85%) followed by 1 min of euoxia] increases mean arterial pressure by 4 (Foster et al. 2009a) , 5 (Tamisier et al. 2009 ) and 7 mmHg (Foster et al. 2010) , respectively. Moreover, hypercapnic IH exposure and voluntary hypoxic apnoeas both mimicking an ODI of 60 for 20 min induce long-lasting elevations in MSNA (Xie et al. 2000; Cutler et al. 2004) . Notably, although MSNA remained elevated for ß20-180 min after the removal of IH in these studies, blood pressure returned to the pre-IH level immediately upon IH removal. This outcome contrasts with other studies reporting both elevated MSNA and elevated blood pressure following 30 min of IH (one 20 s hypoxic apnoea every minute; S aO 2 nadir = 83%) that remained for at least 30 min after the termination of IH . Moreover, 14 nights of IH (2 min of F I,O 2 at 13% followed by 15 s of 100% oxygen for 8-9 h night −1 ) increased daytime MSNA by ß30% and daytime blood pressure by 8 mmHg ). In conclusion, animal and human experimental models confirm that IH increases blood pressure and augments SNA, which are thus likely contributors to the greater risk of vascular disease in OSA.
Endothelial function. The role of IH in promoting endothelial dysfunction was first studied by Tahawi et al. (2001) in rats exposed to very severe IH (ODI = 120) for 35 days (6-8 h day −1 ). In addition to a 16 mmHg elevation in blood pressure, IH decreased acetylcholine-induced vasodilatation in cremaster muscle arterioles, but not sodium nitroprusside-induced vasodilatation (an endothelium-independent response). As hypertension can independently cause endothelial dysfunction, Phillips et al. (2004) assessed endothelial function in rat gracilis and middle cerebral arteries after 14 days (12 h day −1 ) of moderate IH (ODI = 15) that did not increase blood pressure. In both arteries, IH disrupted endothelial function, as acetylcholine-induced vasodilatation decreased, but sodium nitroprusside-induced vasodilatation was maintained. In contrast, both Julien et al. (2003) and Lefebvre et al. (2006) found no change in acetylcholine-induced vasodilatation of mouse hindquarters, aorta, carotid artery or the mesenteric arterial bed following exposure to IH (14 days, 7-8 h day −1 , ODI = 120 and 35 days, 8 h day −1 , ODI = 60, respectively). Although these findings appear conflicting, they probably indicate that resistance vessels are more sensitive to IH-induced endothelial disruption than larger conductance vessels (Foster et al. 2007b) .
Comparable to animal studies, IH has been reported to disrupt human endothelial function. Gilmartin et al. (2010) found that 28 days of IH mimicking an ODI of 30 decreased forearm reactive hyperaemia in response to a 15 min ischaemic challenge (forearm occlusion), a response that is believed to be nitric oxide (i.e. endothelium) dependent. Unfortunately, as forearm reactive hyperaemia was not assessed after removal of IH, it is unclear how long this detriment persisted. Of note, after the initial 14 days of IH, forearm reactive hyperaemia was higher than the pre-IH response. In a follow-up study using the same experimental IH model and a 14 day exposure, Tamisier et al. (2011) found no change in calf reactive hyperaemia following a 5 min occlusion. Likewise, Tremblay et al. (2016) found that 6 h of IH (ODI = 30) did not alter human brachial artery endothelial function assessed by flow-mediated dilatation. Consequently, prolonged IH exposure appears to be a prerequisite to induce endothelial dysfunction, whereas shorter duration IH may not impact or may even provide some beneficial effects to endothelial function, at least for the vascular beds examined in these studies. Nevertheless, we reported that as few as 4 days of IH (6 h day −1 ) mimicking an ODI of 15 is sufficient to alter human plasma exosome cargo, resulting in the exosomes having a greater ability to disrupt endothelial function in vitro, changes that are not apparent 4 days after the removal of IH (Khalyfa et al. 2016) .
Peripheral vascular regulation. Few animal studies have investigated the impact of IH on the peripheral pressor or blood flow responses to hypoxia and hypercapnia. Greenberg et al. (1999) reported that 30 days of IH (ODI = 60; 8 h day −1 ) elevated the pressor response to hypoxic hypercapnia in rats, but not to hypoxia alone. Additionally, Phillips et al. (2004) found that the vasodilatory response of the gracilis artery to hypoxia was absent after 14 days of IH exposure (ODI = 15; 12 h day −1 ). Hence, experimental animal models support IH having a detrimental impact on peripheral vascular regulation, but whether an IH protocol that mimics mild OSA (e.g. 5 ࣙ ODI < 15) might induce beneficial adaptations in peripheral vascular regulation still needs to be determined.
In humans, IH is reported to enhance the pressor response to hypoxia but not hypercapnia following moderate but not mild exposure. After 12 days of mild IH (60 min; 5 min isocapnic hypoxia and 5 min of room air), Foster et al. (2005) and Querido et al. (2015) found no change in the blood pressure response to hypoxia. Foster et al. (2005) also found no impact of IH on the pressor response to hypercapnia. However, the IH protocols used in these studies are very different from that observed in patients with OSA. Subsequently, using an IH model that mimicked moderate OSA-related IH more closely (ODI = 15), Foster et al. (2009a) reported an enhanced blood pressure response to hypoxia after only 4 days (6 h day −1 ) of IH that returned to pre-IH 4 days after the removal of IH. Interestingly, in a follow-up study, the same group found no IH-induced augmentation of the hypoxic pressor response after 6 h of IH that mimicked an ODI of 30 (Foster et al. 2010 ).
Cerebrovascular regulation. The impact of IH on cerebrovascular responses to changes in arterial blood gases has been primarily assessed in humans. In the only animal study, exposure to 14 days (12 h day −1 ) of IH
A. E. Beaudin and others (ODI = 15) abolished the ability of the middle cerebral artery to dilate in response to an acute hypoxic challenge (Phillips et al. 2004) . In accordance with this finding, the CBF response to hypoxia was found to decrease in healthy humans exposed both to 12 days of mild IH that did not mimic OSA-induced IH too closely (i.e. 5 min isocapnic hypoxia and 5 min of room air for 1 h day −1 ) and to 4 days of IH simulating an ODI of 15 (Foster et al. 2005 (Foster et al. , 2009a Querido et al. 2015) . Responses returned to pre-IH values 4-5 days after termination of IH. However, 6 h of IH simulating an ODI of 30 was insufficient to alter the CBF response to hypoxia (Foster et al. 2010) . Hence, a longer duration of IH exposure appears to be necessary to alter the cerebrovascular response to hypoxia. Finally, IH does not appear to impact the CBF response to hypercapnia in healthy humans, with recent studies reporting no change after 10 (Querido et al. 2015) and 14 days of IH (Zhang et al. 2015) . However, the IH protocol used in these two studies (Table 1) is very different from that induced by OSA. Therefore, the impact of OSA-induced IH on the human CBF response to hypercapnia remains poorly understood.
Overall, findings from both animal and human experimental models investigating the detrimental impact of IH upon vascular regulation underline the importance of the IH dose (i.e. duration and frequency) in disrupting vascular regulation. Moreover, the similarity within human experimental IH studies that any detrimental impact of IH upon vascular regulation is corrected (i.e. returns to pre-IH levels) within 4-5 days following the termination of IH highlights an important knowledge gap; we still do not know how much IH (duration and frequency) is required to elicit irreversible vascular changes. In addition, the abrupt onset of IH exposure within experimental models may contribute to some of the discordant results with regard to the impact of IH upon SNA, endothelial function and vascular regulation. Given that the severity of IH develops gradually over time in patients with OSA, the impact of slowly developing IH on vascular regulation still needs further investigation.
Protective effects of intermittent hypoxia.
Cardioprotection. Remote ischaemic preconditioning is protective against subsequent lethal ischaemiareperfusion injury (Hausenloy et al. 2015) . Thus, a certain degree of IH has been suggested to be cardioprotective. To investigate a potential cardioprotective role of IH, Béguin et al. (2005) exposed adult male Wistar rats to normoxia (F I,O 2 = 21%; 30 min, 4 h), continuous hypoxia (F I,O 2 = 10%; 4 h) or four varying 'doses' of IH (30 min with F I,O 2 = 10 or 5% or 4 h with F I,O 2 = 10 or 5%). The IH exposure consisted of alternating cycles of 40 s of hypoxia and 20 s of normoxia during the study period (30 min or 4 h), thus inducing an ODI of 60. Twenty-four hours after the withdrawal of IH, the animals' hearts were removed and exposed to 30 min of ischaemia followed by 120 min of reperfusion. Compared with normoxia, neither continuous hypoxia (4 h) nor 30 min of IH with an F I,O 2 of 10% affected myocardial infarct size. In contrast, the infarct size was greater following 4 h of IH with an F I,O 2 of 5%, but 4 h of IH at an F I,O 2 of 10% provided some cardioprotection, with infarct size being significantly smaller compared with normoxia. The cardioprotection observed in the last group was no longer apparent when rats were treated with the nitric oxide synthase blocker L-NAME (N ɷ -nitro-L-arginine methyl ester) or the mitochondrial ATP-sensitive K + channel blocker 5-hydroxydecanoic acid, suggesting that the cardioprotective effects of IH were modulated by nitric oxide metabolism and mitochondrial ATP-sensitive K + channels. In summary, 4 h of severe IH (F I,O 2 = 5%; ODI = 60) led to deleterious effects, whereas the same pattern of IH (i.e. ODI = 60) but with a slightly higher F I,O 2 (10%) led to cardioprotection. Taken together, these results show that the severity and duration of IH are important determinants of whether IH induces beneficial or detrimental effects.
Cerebral protection. Similar to the heart, mild IH is also reported to provide some ischaemic preconditioning and reduce brain damage during stroke. Jackman et al. (2014) randomly assigned 7-to 13-week-old male C56Bl/6J mice to one of six IH conditions [ODI = 20; F I,O 2 = 10 or 6% (90 s) followed by normoxia (90 s) for 14, 21 or 35 days], after which mice then underwent a 30-35 min middle cerebral artery occlusion, with brain infarct size being assessed 3 days later. Although neither 14 days of IH with an F I,O 2 of 6 and 10% nor 21 days of IH with an F I,O 2 of 10% impacted infarct size, 21 days of IH at an F I,O 2 of 6% exacerbated the brain injury induced by the middle cerebral artery occlusion. Interestingly, 35 days of IH with an F I,O 2 of 10% reduced the infarct volume by ß50%, whereas 35 days of IH with an F I,O 2 of 6% increased the infarct volume. Therefore, like cardioprotection, IH-induced neuroprotection depended upon the duration and severity of IH. It should be noted that although milder IH (F I,O 2 = 10%) for 35 days was protective against cerebral ischaemia, systolic blood pressure was elevated following IH; an outcome that would be associated with an increased risk of stroke (Lewington et al. 2002) . As such, although moderate IH may provide some protection against brain damage after stroke, through increasing blood pressure and disrupting cerebrovascular regulation, IH is still likely to increase the risk of stroke.
In addition, IH has been shown to induce both adaptive and maladaptive neuronal responses (Gozal, 2013; Rosenzweig et al. 2013b Rosenzweig et al. , 2015 depending on the Obstructive sleep apnoea, intermittent hypoxia and vascular regulation duration of IH exposure. In rats, Gozal et al. (2003) found a biphasic pattern of neurogenesis in the dentate gyrus of the hippocampus, with significant reductions in neuronal proliferation during the first 3 days of IH exposure [cycles of 90 s normoxia and 90 s hypoxia (F I,O 2 = 10%); ODI = 20] followed by marked neurogenesis within the hippocampus after 7, 14 and 30 days of IH. This biphasic time course of neuronal events coincided with changes in spatial performance assessed using the Morris water maze as a measure of hippocampal function. However, these divergent neuronal changes appear to be tissue specific, with both decreased thalamic volume and increased Mild OSA has been associated with decreased mortality of patients with cardiometabolic co-morbidities compared with non-OSA individuals having similar co-morbidities, greater muscular/cardiac angiogenesis and cardioprotection or brain tissue protection while mild-to-moderate IH is also reported to decrease infarct size following a heart attack or stroke. With increasing OSA severity and IH exposure from mild to moderate to severe, the risk of vascular disease increases with greater endothelial dysfunction, cerebral blood flow (CBF) response to hypoxia, diminished cerebrovascular autoregulation and altered blood pressure regulation. Finally, the impact of OSA and IH on vascular regulation is diminished with advancing age, with OSA patients >50 years of age and older mice being more resistant to the detrimental effects of IH than OSA patients <50 years of age and young adult mice. This beneficial effect of advancing age on vascular disease risk with OSA may result from ageing-associated decreases in the arousal threshold and greater sleep fragmentation serving to decrease OSA severity and IH exposure. However, data do substantiate that early diagnosis and treatment of OSA is imperative for minimizing cardiovascular and cerebrovascular disease risk.
A. E. Beaudin and others hippocampal volumes having been reported in brains of the same cohort of moderate-to-severe OSA patients (Rosenzweig et al. 2013a) .
In summary, animal and human models show that beneficial effects of IH are principally associated with short cycles of moderate hypoxia of relatively brief duration. Importantly, although IH may improve the resistance of cardiac muscle or brain tissue to ischaemia, this is not likely to be linked to improved vascular health or decreased risk of vascular disease. Intermittent hypoxia can increase the risk of myocardial infarction and stroke, but it may also promote improved outcomes after such events. These findings also suggest that a similar dose of IH can lead to beneficial effects for some organs (i.e. brain and heart) and deleterious effects for others (e.g. vasculature). However, to our knowledge, these two hypotheses have never been investigated.
Intermittent hypoxia and age. It is worth noting that all the aforementioned animal and human experimental IH studies have been performed in young, healthy adult rodents and humans (Table 1 ). The age of the animals and human subjects in experimental IH studies is an important consideration because, as previously indicated, OSA-related mortality has been found to be greater in patients <50 years old. With this underlying premise, Quintero et al. (2016) report that the deleterious vascular effects of IH are modulated by the ageing process. In young rats (3-4 months old), 14 days of IH (ODI = 30) augmented carotid body chemosensory activity, renal sympathetic activity, oxidative stress and plasma C-reactive protein concentrations. In contrast, older rats (22-24 months old) exposed to the same IH experienced significantly lower carotid body chemosensory activity augmentation and renal sympathetic activity, redox imbalance and plasma C-reactive protein concentrations. Additionally, although older rats had higher blood pressure compared with young rats before the IH exposure, blood pressure was not changed after IH in older rats, whereas it was increased in the young rats after IH exposure. Interestingly, before IH exposure, older rats also had higher brain catalase activity, increased mitochondrial superoxide dismutase and glutathione peroxidase activity, and reduced lipid peroxidation in lungs, brain and liver compared with young rats. Following IH, catalase activity in the liver, brain and lungs was increased in older rats, whereas in young rats there was a 50% decrease in catalase activity in the same tissues. These findings suggest the presence of better redox status and redox response to chronic IH in older rats compared with young rats, which may protect them from further vascular alterations. These observations provide a potential explanation for the lower OSA-related mortality risk in patients >50 years of age (He et al. 1988; Lavie, 2007) .
Perspectives and conclusion
We reviewed the literature demonstrating that chronic IH can have either detrimental or beneficial effects depending on the magnitude of the hypoxic stimuli and the duration of exposure (Fig. 2) . In addition, the detrimental or beneficial effects of mild OSA appear to be associated with age, with older patients being less sensitive to the detrimental effects of IH than young OSA patients. This suggests that early diagnosis and treatment of OSA is imperative for minimizing cardiovascular and cerebrovascular disease risk. We showed that OSA leads to detrimental cardio-and cerebrovascular outcomes. However, although this is particularly true for severe OSA, it remains unclear in patients with mild OSA. The literature shows that mild OSA could promote muscular/cardiac angiogenesis, cardioprotection or brain tissue protection. It has also been reported that the mortality rate is decreased in mild OSA patients compared with non-OSA subjects, only when the risk calculation is adjusted for confounding factors. Thus, it could be argued that mild OSA protects against the effects of other cardiovascular risk factors so that patients with mild OSA and multiple risk factors have a lower mortality risk than non-OSA patients with similar co-morbidities. In this way, the beneficial effects of mild OSA are very relative. Furthermore, the effect of mild OSA on the peripheral and central vasculature seems to be less conclusive, because, for instance, mild OSA patients are characterized by a higher prevalence of hypertension compared with non-OSA subjects. Therefore, the dose-response relationship for IH, in the context of OSA, may be tissue specific.
Future studies are needed to investigate the effects of OSA (in patients) and IH (in experimental models) simultaneously on different tissues. Large prospective longitudinal studies are also clearly needed to test the conditions in which mild OSA might be beneficial.
